As a supplier of raloxifene powder, I often receive inquiries from various research institutions, pharmaceutical companies, and individuals about the properties, applications, and safety of raloxifene. One of the most common questions that has come up recently is whether raloxifene powder can be used during pregnancy. In this blog, I will delve into this topic, providing a comprehensive analysis based on scientific research and medical knowledge.
Raloxifene Powder
Product Code: BM-2-5-047
Eng Name: Raloxifene
CAS number: 84449-90-1
MF.: C28H27NO4S
Molecular weight: 473.58
EINECS number: 686-786-1
HS code: 29349990
Main market: USA, Australia, Brazil, Japan, Germany, Indonesia, UK, New Zealand , Canada etc.
Manufacturer: BLOOM TECH Wuxi Factory
Technology service: R&D Dept.-2
We provide raloxifene powder, please refer to the following website for detailed specifications and product information.
Understanding Raloxifene Powder
Raloxifene is a selective estrogen receptor modulator (SERM). It acts on estrogen receptors in different tissues in the body, producing estrogen-like or anti-estrogen effects depending on the tissue type. In the bone, raloxifene mimics the beneficial effects of estrogen, helping to maintain bone density and reduce the risk of osteoporosis. In breast tissue, it has anti-estrogenic effects, which may help in reducing the risk of breast cancer.
Our company offers high-quality raloxifene powder that meets strict quality standards. It is mainly used for scientific research purposes, including drug development and pre-clinical studies. We also supply other research chemicals such as Ligandrol (LGD-4033), Puerarin Powder CAS 3681-99-0, and Imidacloprid Powder CAS 138261-41-3, all of which are intended for research use only.
The Risks of Using Raloxifene During Pregnancy
Pregnancy is a delicate period during which the health and development of both the mother and the fetus need to be carefully considered. When it comes to raloxifene, there are significant concerns about its use during pregnancy.
Teratogenic Effects in Animal Studies
Numerous animal studies have indicated that raloxifene can cause teratogenic (birth-defect-causing) effects. In pregnant rats and rabbits, exposure to raloxifene during critical periods of organogenesis has led to an increased incidence of structural malformations in the offspring. These malformations involve multiple organ systems, including the skeletal, cardiovascular, and urogenital systems. For example, studies have shown that high-dose raloxifene administration in pregnant rats can result in limb and craniofacial abnormalities in the fetuses.
Estrogen-like and Anti-estrogen Effects on the Fetus
Since raloxifene is a SERM, it can interact with estrogen receptors in the developing fetus. The normal development of the fetus is tightly regulated by the hormonal environment, and any disruption in estrogen signaling can have profound consequences. In the female fetus, abnormal estrogenic or anti-estrogenic effects may interfere with the development of the reproductive system, potentially leading to fertility issues later in life. In male fetuses, exposure to raloxifene may affect the normal development of the testes and other reproductive organs.
Lack of Safety Data in Humans
There are limited studies on the use of raloxifene in pregnant women. Due to the potential risks suggested by animal studies, it is unethical to conduct large-scale clinical trials on pregnant women. As a result, there is a lack of reliable safety data in humans. Without clear evidence of safety, using raloxifene during pregnancy is extremely risky.
Medical Recommendations
Based on the available scientific evidence, medical professionals strongly advise against the use of raloxifene during pregnancy. Raloxifene is classified as a pregnancy category X drug by the U.S. Food and Drug Administration (FDA). This means that studies in animals or humans have demonstrated fetal abnormalities and/or there is positive evidence of human fetal risk based on adverse reaction data from investigational or marketing experience, and the risks involved in use of the drug in pregnant women clearly outweigh any possible benefits.
If a woman is planning to become pregnant, she should stop taking raloxifene well in advance. In case of accidental exposure to raloxifene during pregnancy, immediate medical advice should be sought. The doctor will assess the situation, taking into account the stage of pregnancy, the dose of raloxifene exposed, and other relevant factors, to provide appropriate guidance and monitoring.
Our Role as a Supplier
As a raloxifene powder supplier, we play a crucial role in ensuring that our customers are well-informed about the proper use and safety considerations of our products. We always emphasize that our raloxifene powder is for research purposes only and not for human consumption, especially not for use during pregnancy.
We provide detailed product information, including safety data sheets, to our customers. These documents contain information about the chemical properties, potential hazards, and handling precautions of raloxifene. We also encourage our customers to conduct their own research and consult with relevant experts to ensure the safe and appropriate use of our products.
If you are involved in scientific research related to raloxifene or other research chemicals, we are here to support you. Our high-quality raloxifene powder can meet your research needs. Whether you are studying its potential therapeutic applications, its mechanism of action, or its interaction with other substances, our product can be a reliable choice.
If you are interested in purchasing raloxifene powder or other research chemicals such as Ligandrol (LGD-4033), Puerarin Powder CAS 3681-99-0, and Imidacloprid Powder CAS 138261-41-3, please feel free to contact us for further discussion. We are looking forward to establishing a long-term cooperative relationship with you and contributing to your scientific research.
References
- Black, L. J., et al. (1994). Raloxifene (LY139481 HCl) prevents bone loss and reduces serum cholesterol without causing uterine hypertrophy in ovariectomized rats. Journal of Clinical Investigation, 93(6), 2349-2358.
- Delmas, P. D., et al. (1997). Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. New England Journal of Medicine, 337(23), 1641-1647.
- Kauffman, R. E., et al. (2000). Teratogenicity of raloxifene in rats and rabbits. Reproductive Toxicology, 14(3), 233-243.